{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T04:43:58Z","timestamp":1785386638304,"version":"3.55.0"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"5-6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Mol Med"],"published-print":{"date-parts":[[2011,5]]},"DOI":"10.2119\/molmed.2011.00030","type":"journal-article","created":{"date-parts":[[2011,5,26]],"date-time":"2011-05-26T14:11:30Z","timestamp":1306419090000},"page":"397-403","source":"Crossref","is-referenced-by-count":107,"title":["HDAC Inhibition in Rheumatoid Arthritis and Juvenile Idiopathic Arthritis"],"prefix":"10.1186","volume":"17","author":[{"given":"Jelena","family":"Vojinovic","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nemanja","family":"Damjanov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,2,4]]},"reference":[{"key":"1705397_CR1","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1146\/annurev.pathol.4.110807.092254","volume":"4","author":"JB Imboden","year":"2009","unstructured":"Imboden JB. (2009) The immunopathogenesis of rheumatoid arthritis. Annu. Rev. Pathol. 4:417\u201334.","journal-title":"Annu. Rev. Pathol."},{"key":"1705397_CR2","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1056\/NEJM200103223441207","volume":"344","author":"EH Choy","year":"2001","unstructured":"Choy EH, Panayi GS. (2001) Cytokine pathways and joint inflammation in rheumatoid arthritis. N. Engl. J. Med. 344:907\u201316.","journal-title":"N. Engl. J. Med."},{"key":"1705397_CR3","first-page":"390","volume":"31","author":"RE Petty","year":"2004","unstructured":"Petty RE et al. (2004) International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J. Rheumatol. 31:390\u201392.","journal-title":"J. Rheumatol."},{"key":"1705397_CR4","doi-asserted-by":"publisher","first-page":"3537","DOI":"10.1172\/JCI36389","volume":"118","author":"FM Brennan","year":"2008","unstructured":"Brennan FM, McInnes IB. (2008) Evidence that cytokines play a role in rheumatoid arthritis. J. Clin. Invest.118:3537\u201345.","journal-title":"J. Clin. Invest."},{"key":"1705397_CR5","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.bbrc.2010.05.111","volume":"397","author":"X Li","year":"2010","unstructured":"Li X et al. (2010) The role of interleukin-17 in mediating joint destruction in rheumatoid arthritis. Biochem. Biophys. Res. Commun. 397:131\u20135.","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"1705397_CR6","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.2353\/ajpath.2007.070004","volume":"171","author":"CN Tran","year":"2007","unstructured":"Tran CN et al. (2007) Molecular interactions between T cells and fibroblast-like synoviocytes: role of membrane tumor necrosis factor-alpha on cytokine-activated T cells. Am. J. Pathol. 171:1588\u201398.","journal-title":"Am. J. Pathol."},{"key":"1705397_CR7","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s00441-009-0887-6","volume":"339","author":"TE Cawston","year":"2010","unstructured":"Cawston TE, Young DA. (2010) Proteinases involved in matrix turnover cartilage and bone breakdown. Cell Tissue Res. 339:221\u201335.","journal-title":"Cell Tissue Res."},{"key":"1705397_CR8","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1078\/0171-2985-00194","volume":"206","author":"H Mangge","year":"2002","unstructured":"Mangge H, hours, ovic J, Schauenstein K. (2002) Do chemokines spark autoimmunity in juvenile and adult rheumatic disease? Immunobiology. 206:459\u201371.","journal-title":"Immunobiology"},{"key":"1705397_CR9","doi-asserted-by":"publisher","first-page":"3523","DOI":"10.1002\/art.22948","volume":"56","author":"LC Huber","year":"2007","unstructured":"Huber LC, Stanczyk J, J\u00fcngel A, Gay S. (2007) Epigenetics in inflammatory rheumatic diseases. Arthritis Rheum. 56:3523\u201331.","journal-title":"Arthritis Rheum."},{"key":"1705397_CR10","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1097\/BOR.0b013e3283389641","volume":"22","author":"A J\u00fcngel","year":"2010","unstructured":"J\u00fcngel A, Ospelt C, Gay S. (2010) What can we learn from epigenetics in the year 2009? Curr. Opin. Rheumatol. 22:284\u201392.","journal-title":"Curr. Opin. Rheumatol."},{"key":"1705397_CR11","doi-asserted-by":"publisher","first-page":"2584","DOI":"10.2174\/138161207781663064","volume":"13","author":"G Elaut","year":"2007","unstructured":"Elaut G, Rogiers V, Vanhaecke T. (2007) The pharmaceutical potential of histone deacetylase inhibitors. Curr. Pharm. Des. 13:2584\u2013620.","journal-title":"Curr. Pharm. Des."},{"key":"1705397_CR12","doi-asserted-by":"publisher","first-page":"2718","DOI":"10.4049\/jimmunol.0901467","volume":"184","author":"AM Grabiec","year":"2010","unstructured":"Grabiec AM, et al. (2010) Histone deacetylase inhibitors suppress inflammatory activation of rheumatoid arthritis patient synovial macrophages and tissue. J. Immunol. 184:2718\u201328.","journal-title":"J. Immunol."},{"key":"1705397_CR13","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.molimm.2009.01.010","volume":"47","author":"H Maciejewska Rodrigues","year":"2009","unstructured":"Maciejewska Rodrigues H, Jungel A, Gay ER, Steffen G. (2009) Innate immunity, epigenetics and autoimmunity in rheumatoid arthritis. Mol. Immunol. 47:12\u20138.","journal-title":"Mol. Immunol."},{"key":"1705397_CR14","doi-asserted-by":"publisher","first-page":"309","DOI":"10.2174\/156802609788085250","volume":"9","author":"MA Halili","year":"2009","unstructured":"Halili MA, Andrews MR, Sweet MJ, Fairlie DP. (2009) Histone deacetylase inhibitors in inflammatory disease. Curr. Top. Med. Chem. 9:309\u201319.","journal-title":"Curr. Top. Med. Chem."},{"key":"1705397_CR15","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1038\/ni0901-759","volume":"2","author":"J Ermann","year":"2001","unstructured":"Ermann J, Fathman CG. (2001) Autoimmune diseases: genes, bugs and failed regulation. Nat. Immunol. 2:759\u201361.","journal-title":"Nat. Immunol."},{"key":"1705397_CR16","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1111\/j.0105-2896.2009.00862.x","volume":"233","author":"LA Criswell","year":"2010","unstructured":"Criswell LA. (2010) Gene discovery in rheumatoid arthritis highlights the CD40\/NF-kappaB signaling pathway in disease pathogenesis. Immunol. Rev. 233:55\u201361.","journal-title":"Immunol. Rev."},{"key":"1705397_CR17","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.biocel.2008.08.023","volume":"41","author":"L B\u00e4ckdahl","year":"2010","unstructured":"B\u00e4ckdahl L, Bushell A, Beck S. (2010) Inflammatory signalling as mediator of epigenetic modulation in tissue-specific chronic inflammation. Int. J. Biochem. Cell Biol. 41:176\u201384.","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"1705397_CR18","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1002\/art.30238","volume":"63","author":"J Vojinovic","year":"2011","unstructured":"Vojinovic J, et al. (2011) Safety and efficacy of an oral histone deacetylase inhibitor in systemic-onset juvenile idiopathic arthritis. Arthritis Rheum. 63:1452\u20138.","journal-title":"Arthritis Rheum."},{"key":"1705397_CR19","first-page":"2071","volume":"31","author":"JW Verbsky","year":"2004","unstructured":"Verbsky JW, White AJ. (2004) Effective use of the recombinant interleukin 1 receptor antagonist anakinra in therapy resistant systemic onset juvenile rheumatoid arthritis. J. Rheumatol. 31:2071\u20135.","journal-title":"J. Rheumatol."},{"key":"1705397_CR20","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1016\/S0140-6736(08)60454-7","volume":"371","author":"S Yokota","year":"2008","unstructured":"Yokota S, et al. (2008) Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, doubleblind, placebo-controlled, withdrawal phase III trial. Lancet. 371:998\u20131006.","journal-title":"Lancet"},{"key":"1705397_CR21","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1136\/ard.2003.014886","volume":"63","author":"G Horneff","year":"2004","unstructured":"Horneff G, et al. (2004) The German etanercept registry for treatment of juvenile idiopathic arthritis. Ann. Rheum. Dis. 63:1638\u201344.","journal-title":"Ann. Rheum. Dis."},{"key":"1705397_CR22","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1016\/j.autrev.2010.04.002","volume":"9","author":"C Papagoras","year":"2010","unstructured":"Papagoras C, Voulgari PV, Drosos AA. (2010) Strategies after the failure of the first anti-tumor necrosis factor alpha agent in rheumatoid arthritis. Autoimmun. Rev. 9:574\u201382.","journal-title":"Autoimmun. Rev."},{"key":"1705397_CR23","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1136\/ard.2009.126532","volume":"69","author":"JS Smolen","year":"2010","unstructured":"Smolen JS, et al. (2010): EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann. Rheum. Dis. 69:964\u201375.","journal-title":"Ann. Rheum. Dis."},{"key":"1705397_CR24","doi-asserted-by":"publisher","first-page":"353","DOI":"10.2119\/molmed.2011.00020","volume":"17","author":"A Furlan","year":"2011","unstructured":"Furlan A, et al. (2011) Pharmacokinetics, safety and inducible cytokine responses during a phase 1 trial of the oral histone deacetylase inhibitor ITF2357 (givinostat). Mol. Med. 17:353\u2013362.","journal-title":"Mol. Med."},{"key":"1705397_CR25","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1002\/1529-0131(199707)40:7<1202::AID-ART3>3.0.CO;2-R","volume":"40","author":"EH Giannini","year":"1997","unstructured":"Giannini EH, et al. (1997) Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum. 40:1202\u20139.","journal-title":"Arthritis Rheum."},{"key":"1705397_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2119\/2006-00005.Dinarello","volume":"11","author":"F Leoni","year":"2005","unstructured":"Leoni F, et al. (2005) The histone deacetylase inhibitor ITF2357 reduces production of proinflammatory cytokines in vitro and systemic inflammation in vivo. Mol. Med. 11:1\u201315.","journal-title":"Mol. Med."},{"key":"1705397_CR27","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1084\/jem.20050473","volume":"201","author":"V Pascual","year":"2005","unstructured":"Pascual V, Allantaz F, Arce E, Punaro M, Banchereau J. (2005) Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. J. Exp. Med. 201:1479\u201386.","journal-title":"J. Exp. Med."},{"key":"1705397_CR28","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1056\/NEJMoa055137","volume":"355","author":"R Goldbach-Mansky","year":"2006","unstructured":"Goldbach-Mansky R, et al. (2006) Neonatal-onset multisystem inflammatory disease responsive to interleukin-1beta inhibition. N. Engl. J. Med. 355:581\u201392.","journal-title":"N. Engl. J. Med."},{"key":"1705397_CR29","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1136\/ard.2007.076034","volume":"67","author":"T Lequerre","year":"2008","unstructured":"Lequerre T, et al. (2008) Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France. Ann Rheum Dis. 67:302\u20138.","journal-title":"Ann Rheum Dis."},{"key":"1705397_CR30","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1056\/NEJM199204163261602","volume":"326","author":"EH Giannini","year":"1992","unstructured":"Giannini EH, et al. (1992) Results of the U.S.A.-U.S.S.R. double-blind, placebo-controlled trial. The Pediatric Rheumatology Collaborative Study Group and The Cooperative Children\u2019s Study Group. N. Engl. J. Med. 326:1043\u20139.","journal-title":"N. Engl. J. Med."},{"key":"1705397_CR31","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/j.berh.2009.08.003","volume":"23","author":"SJ Vastert","year":"2009","unstructured":"Vastert SJ, Kuis W, Grom AA. (2009) Systemic JIA: new developments in the understanding of the pathophysiology and therapy. Best Pract. Res. Clin. Rheumatol. 23:655\u201364.","journal-title":"Best Pract. Res. Clin. Rheumatol."},{"key":"1705397_CR32","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1002\/art.20288","volume":"50","author":"N Ruperto","year":"2004","unstructured":"Ruperto N, et al. (2004) A randomized trial of parenteral methotrexate comparing an intermediate dose with a higher dose in children with juvenile idiopathic arthritis who failed to respond to standard doses of methotrexate. Arthritis Rheum. 50:2191\u2013201.","journal-title":"Arthritis Rheum."},{"key":"1705397_CR33","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1001\/jama.2010.375","volume":"303","author":"D Foel","year":"2010","unstructured":"Foel D, et al. (2010) Methotrexate withdrawal at 6 vs 12 months in juvenile idiopathic arthritis in remission: a randomized clinical trial. JAMA. 303:1266\u201373.","journal-title":"JAMA"},{"key":"1705397_CR34","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1007\/s10067-008-0995-9","volume":"28","author":"N Ilowite","year":"2009","unstructured":"Ilowite N, et al.(2009). Anakinra in the treatment of polyarticular-course juvenile rheumatoid arthritis: safety and preliminary efficacy results of a randomized multicenter study. Clin. Rheumatol. 28:129\u201337.","journal-title":"Clin. Rheumatol."},{"key":"1705397_CR35","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1002\/art.23437","volume":"58","author":"M Gattorno","year":"2008","unstructured":"Gattorno M, et al. (2008). The pattern of response to anti-interleukin-1 treatment distinguishes two subsets of patients with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum. 58:1505\u201315.","journal-title":"Arthritis Rheum."},{"key":"1705397_CR36","doi-asserted-by":"publisher","first-page":"3697","DOI":"10.1073\/pnas.0500369102","volume":"102","author":"MJ Peart","year":"2005","unstructured":"Peart MJ, et al. (2005) Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors. Proc. Natl. Acad. Sci. U.S.A. 102:3697\u2013702.","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"1705397_CR37","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/S1359-6446(04)03309-4","volume":"10","author":"F Blenchard","year":"2005","unstructured":"Blenchard F, Chipoy C. (2005) Histone deacetylase inhibitors: new drugs for the treatment of inflammatory disease. Drug Disc. Today. 10:197\u2013204.","journal-title":"Drug Disc. Today"},{"key":"1705397_CR38","doi-asserted-by":"publisher","first-page":"R133","DOI":"10.1186\/ar3071","volume":"12","author":"T Kawabata","year":"2010","unstructured":"Kawabata T, et al. (2010) Increased activity and expression of histone deacetylase 1 in relation to tumor necrosis factor-alpha in synovial tissue of rheumatoid arthritis. Arthritis Res. Ther. 12:R133.","journal-title":"Arthritis Res. Ther."},{"key":"1705397_CR39","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.3899\/jrheum.081115","volume":"36","author":"M Horiuchi","year":"2009","unstructured":"Horiuchi M, et al. (2009) Expression and function of histone deacetylases in rheumatoid arthritis synovial fibroblasts. J. Rheumatol. 36:1580\u20139.","journal-title":"J. Rheumatol."},{"key":"1705397_CR40","doi-asserted-by":"publisher","first-page":"2995","DOI":"10.1073\/pnas.052702999","volume":"99","author":"F Leoni","year":"2002","unstructured":"Leoni F, et al. (2002) The antitumor histone deacetylase inhibitor suberoylanilide hydroxamic acid exhibits antiinflammatory properties via suppression of cytokines. Proc. Natl. Acad. Sci. U.S.A. 99:2995\u20133000.","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"1705397_CR41","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/S1525-0016(03)00235-1","volume":"8","author":"YL Chung","year":"2003","unstructured":"Chung YL, Lee MY, Wang AJ, Yao LF. (2003) A therapeutic strategy uses histone deacetylase inhibitors to modulate the expression of genes involved in the pathogenesis of rheumatoid arthritis. Mol. Ther. 8:707\u201317.","journal-title":"Mol. Ther."},{"key":"1705397_CR42","doi-asserted-by":"publisher","first-page":"3365","DOI":"10.1002\/art.20709","volume":"50","author":"K Nishida","year":"2004","unstructured":"Nishida K, et al. (2004) Histone deacetylase inhibitor suppression of autoantibody mediated arthritis in mice via regulation of p16INK4a and p21(WAF1\/Cip1) expression. Arthritis Rheum. 50:3365\u201376.","journal-title":"Arthritis Rheum."},{"key":"1705397_CR43","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1038\/sj.bjp.0707165","volume":"150","author":"HS Lin","year":"2007","unstructured":"Lin HS, et al. (2007) Anti-rheumatic activities of histone deacetylase (HDAC) inhibitors in vivo in collagen-induced arthritis in rodents. Br. J. Pharmacol. 150:862\u201372.","journal-title":"Br. J. Pharmacol."},{"key":"1705397_CR44","doi-asserted-by":"publisher","first-page":"391","DOI":"10.2119\/molmed.2011.00058","volume":"17","author":"LAB Joosten","year":"2011","unstructured":"Joosten LAB, Leoni F, Meghji S, Mascagni P. (2011) Inhibition of HDAC activity by ITF2357 ameliorates joint inflammation and prevents cartilage and bone destruction in experimental arthritis. Mol. Med. 17:391\u2013396.","journal-title":"Mol. Med."},{"key":"1705397_CR45","doi-asserted-by":"publisher","first-page":"1618","DOI":"10.1182\/blood-2006-03-014126","volume":"108","author":"S Carta","year":"2006","unstructured":"Carta S, et al. (2006) Histone deacetylase inhibitors prevent exocytosis of interleukin-1beta-containing secretory lysosomes: role of microtubules. Blood. 108:1618\u201326.","journal-title":"Blood"},{"key":"1705397_CR46","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1016\/j.intimp.2006.07.001","volume":"6","author":"RE Edens","year":"2006","unstructured":"Edens RE, Dagtas S, Gilbert KM. (2006) Histone deacetylase inhibitors induce antigen specific anergy in lymphocytes: a comparative study. Int. Immunopharmacol. 6:1673\u201381.","journal-title":"Int. Immunopharmacol."},{"key":"1705397_CR47","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1093\/rheumatology\/keq108","volume":"49","author":"QY Choo","year":"2010","unstructured":"Choo QY, Ho PC, Tanaka Y, Lin HS. (2010) Histone deacetylase inhibitors MS-275 and SAHA induced growth arrest and suppressed lipopolysaccharide-stimulated NF-iB p65 nuclear accumulation in human rheumatoid arthritis synovial fibroblastic E11 cells. Rheumatology. 49:1447\u201360.","journal-title":"Rheumatology"},{"key":"1705397_CR48","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1182\/blood-2006-04-019711","volume":"109","author":"JL Brogdon","year":"2007","unstructured":"Brogdon JL, et al. (2007) Histone deacetylase activities are required for innate immune cell control of Th1 but not Th2 effector cell function. Blood. 109:1123\u201330.","journal-title":"Blood"},{"key":"1705397_CR49","first-page":"2562","volume":"118","author":"P Reddy","year":"2008","unstructured":"Reddy P, et al. (2008) Histone deacetylase inhibition modulates indoleamine 2,3-dioxygenase-dependent DC functions and regulates experimental graft-versus-host disease in mice. J. Clin. Invest. 118:2562\u201373.","journal-title":"J. Clin. Invest."},{"key":"1705397_CR50","doi-asserted-by":"publisher","first-page":"3933","DOI":"10.1158\/1078-0432.CCR-06-2903","volume":"13","author":"A Nencioni","year":"2007","unstructured":"Nencioni A, et al. (2007) Histone deacetylase inhibitors affect dendritic cell differentiation and immunogenicity. Clin. Cancer Res.13:3933\u201341.","journal-title":"Clin. Cancer Res."},{"key":"1705397_CR51","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1038\/nm1652","volume":"13","author":"R Tao","year":"2007","unstructured":"Tao R, et al. (2007) Deacetylase inhibition promotes the generation and function of regulatory T cells. Nat. Med.13:1299\u2013307.","journal-title":"Nat. Med."},{"key":"1705397_CR52","doi-asserted-by":"publisher","first-page":"838","DOI":"10.4049\/jimmunol.170.2.838","volume":"170","author":"H Perlman","year":"2003","unstructured":"Perlman H, et al. (2003) IL-6 and matrix metalloproteinase-1 are regulated by the cyclindependent kinase inhibitor p21 in synovial fibroblasts. J. Immunol.170:838\u201345.","journal-title":"J. Immunol."},{"key":"1705397_CR53","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1183\/09031936.00084808","volume":"34","author":"Z Wang","year":"2009","unstructured":"Wang Z, et al. (2009) SAHA-a potential epigenetic therapeutic agent for lung fibrosis? Eur. Respir. J. 34:145\u201355.","journal-title":"Eur. Respir. J."},{"key":"1705397_CR54","doi-asserted-by":"publisher","first-page":"R503","DOI":"10.1186\/ar1702","volume":"7","author":"DA Young","year":"2005","unstructured":"Young DA, et al. (2005) Histone deacetylase inhibitors modulate metalloproteinase gene expression in chondrocytes and block cartilage resorption. Arthrit. Res. Ther. 7:R503\u201312.","journal-title":"Arthrit. Res. Ther."},{"key":"1705397_CR55","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1016\/j.joca.2007.10.014","volume":"16","author":"Y Nasu","year":"2008","unstructured":"Nasu Y, et al. (2008) Trichostatin A, a histone deacetylase inhibitor, suppresses synovial inflammation and subsequent cartilage destruction in a collagen antibody-induced arthritis mouse model. Osteoarthr. Cartil.16:723\u201332.","journal-title":"Osteoarthr. Cartil."},{"key":"1705397_CR56","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1007\/s00011-007-7036-z","volume":"57","author":"H Manabe","year":"2008","unstructured":"Manabe H, et al. (2008). Inhibition of histone deacetylase down-regulates the expression of hypoxia-induced vascular endothelial growth factor by rheumatoid synovial fibroblasts. Inflamm. Res. 57:4\u201310.","journal-title":"Inflamm. Res."},{"key":"1705397_CR57","doi-asserted-by":"publisher","first-page":"5809","DOI":"10.4049\/jimmunol.175.9.5809","volume":"175","author":"T Nakamura","year":"2005","unstructured":"Nakamura T, et al. (2005) Inhibition of histone deacetylase suppresses osteoclastogenesis and bone destruction by inducing IFN-beta production. J. Immunol. 175:5809\u201316.","journal-title":"J. Immunol."},{"key":"1705397_CR58","doi-asserted-by":"publisher","first-page":"4809","DOI":"10.1021\/jm060554y","volume":"49","author":"T Suzuki","year":"2006","unstructured":"Suzuki T, et al. (2006) Highly potent and selective histone deacetylase 6 inhibitors designed based on a small-molecular substrate. J. Med. Chem. 49:4809\u201312.","journal-title":"J. Med. Chem."},{"key":"1705397_CR59","doi-asserted-by":"publisher","first-page":"2254","DOI":"10.1359\/JBMR.050813","volume":"20","author":"TM Schroeder","year":"2005","unstructured":"Schroeder TM, Westendorf JJ. (2005) Histone deacetylase inhibitors promote osteoblast maturation. J. Bone Miner. Res. 20:2254\u201363.","journal-title":"J. Bone Miner. Res."},{"key":"1705397_CR60","doi-asserted-by":"publisher","first-page":"369","DOI":"10.2119\/molmed.2010.00152","volume":"17","author":"EC Lewis","year":"2011","unstructured":"Lewis EC, et al. (2011) The oral histone deacetylase inhibitor ITF2357 reduces cytokines and protects islet \u03b2 cells in vivo and in vitro. Mol. Med. 17:369\u2013377.","journal-title":"Mol. Med."}],"container-title":["Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.crossref.org\/molmed.2011.00030","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.2119\/molmed.2011.00030.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,6]],"date-time":"2019-04-06T04:46:09Z","timestamp":1554525969000},"score":1,"resource":{"primary":{"URL":"https:\/\/molmed.biomedcentral.com\/articles\/10.2119\/molmed.2011.00030"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,2,4]]},"references-count":60,"journal-issue":{"issue":"5-6","published-print":{"date-parts":[[2011,5]]}},"alternative-id":["1705397"],"URL":"https:\/\/doi.org\/10.2119\/molmed.2011.00030","relation":{},"ISSN":["1076-1551","1528-3658"],"issn-type":[{"value":"1076-1551","type":"print"},{"value":"1528-3658","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,2,4]]}}}